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Ixonnexin from Tick Saliva 
Promotes Fibrinolysis by 
Interacting with Plasminogen and 
Tissue-Type Plasminogen Activator, 
and Prevents Arterial Thrombosis
Teresa C. Assumpção1, Daniella M. Mizurini2, Dongying Ma1, Robson Q. Monteiro2,  
Sydney Ahlstedt3, Morayma Reyes3, Michail Kotsyfakis  4, Thomas N. Mather5,  
John F. Andersen1, Jan Lukszo1, José M. C. Ribeiro1 & Ivo M. B. Francischetti  1
Tick saliva is a rich source of modulators of vascular biology. We have characterized Ixonnexin, a 
member of the “Basic-tail” family of salivary proteins from the tick Ixodes scapularis. Ixonnexin is a 104 
residues (11.8 KDa), non-enzymatic basic protein which contains 3 disulfide bonds and a C-terminal 
rich in lysine. It is homologous to SALP14, a tick salivary FXa anticoagulant. Ixonnexin was produced 
by ligation of synthesized fragments (51–104) and (1–50) followed by folding. Ixonnexin, like SALP14, 
interacts with FXa. Notably, Ixonnexin also modulates fibrinolysis in vitro by a unique salivary 
mechanism. Accordingly, it accelerates plasminogen activation by tissue-type plasminogen activator 
(t-PA) with Km 100 nM; however, it does not affect urokinase-mediated fibrinolysis. Additionally, lysine 
analogue ε-aminocaproic acid inhibits Ixonnexin-mediated plasmin generation implying that lysine-
binding sites of Kringle domain(s) of plasminogen or t-PA are involved in this process. Moreover, surface 
plasmon resonance experiments shows that Ixonnexin binds t-PA, and plasminogen (KD 10 nM), but 
not urokinase. These results imply that Ixonnexin promotes fibrinolysis by supporting the interaction 
of plasminogen with t-PA through formation of an enzymatically productive ternary complex. Finally, 
in vivo experiments demonstrates that Ixonnexin inhibits FeCl3-induced thrombosis in mice. Ixonnexin 
emerges as novel modulator of fibrinolysis which may also affect parasite-vector-host interactions.
The coagulation cascade is a series of limited proteolytic reactions, which culminates with thrombin generation 
and fibrin formation1,2. It is a tightly regulated process under control of 3 important anticoagulants including 
Tissue Factor Pathway Inhibitor (TFPI), Antithrombin (AT) and Activated Protein C (APC)1,2. Additionally, 
hemostasis is regulated by the fibrinolytic system that prevents excess thrombus formation by a mechanism 
where plasminogen activation by tissue-type plasminogen activator (t-PA) is amplified by cross-linked fibrin, 
which displays C-terminal lysine3–5. This interaction is mediated by lysine binding sites (LBS) present in the 
finger domain and Kringle 2 of t-PA, and one or more of the Kringle domains in plasminogen6. Also, C-terminal 
lysine generated by plasmin are particularly important as a positive feedback mechanism for the stimulation of 
fibrinolysis6. Fibrinolytic cascade and thrombus formation are regulated by at least 3 physiological inhibitors, 
including alpha2-antiplasmin (A2P), Plasminogen Activator Inhibitor (PAI)-1, and -2, and Thrombin Activatable 
Fibrinolysis Inhibitor (TAFI)7,8.
Salivary glands of blood-sucking arthropods display a notable repertoire of modulators of vascular biol-
ogy. Several molecules have been characterized, including vasodilators, anticoagulants in addition to platelet 
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aggregation and complement inhibitors9–15. These molecules block host response to injury therefore contributing 
to successful blood feeding. Surprisingly, few pro-fibrinolytic components have been identified in ticks, including 
metalloproteases16,17, an inhibitor of TAFI18 and plasminogen receptor enolase19. Fibrinolytic components are 
also important in parasite-vector-host interactions20–26. For instance, in Lyme Disease, a vector-borne disease 
transmitted by the tick Ixodes scapularis, fibrinolysis plays a critical role in Borrelia sp. dissemination, according 
to experiments with knock-out (KO) mice lacking plasminogen27.
More recently, next generation sequencing allowed a remarkable expansion in our understanding of the com-
plexity of the salivary glands of blood-sucking arthropods28,29. However, some biological functions described in 
the salivary gland have not been associated with a specific protein. Likewise, several proteins coded by their cor-
responding salivary gland transcripts remain without a defined function. Among those is the “Basic-tail” family 
of proteins30 which is expanded in ticks and includes members such as SALP14, a Factor Xa (FXa) inhibitor31. 
We have identified Ixonnexin, a SALP14 homologue, as a novel fibrinolytic modulator by a mechanism involving 
binding to plasminogen and t-PA resulting in plasmin generation.
Results
Synthesis of Ixonnexin, a member of the “Basic-tail” family of salivary proteins. Figure 1A 
shows the sequence alignment of several members of the “Basic-tail” family of salivary proteins from Ixodes 
sp. One of its members, named Ixonnexin, is 83% identical to SALP14, a FXa inhibitor31. These proteins have a 
molecular weight of ~11 kDa, and characteristically exhibit 6 cysteine residues and a C-terminal rich in lysine. 
Other members of this family have a naturally deleted C-terminal; for instance, TSLPI from I. scapularis is devoid 
of lysine-rich “basic tail”, and inhibits complement32. A phylogenetic tree of the Ixonnexin family members shows 
that it is particularly expanded in the salivary glands of Ixodes sp and other ticks (not shown).
In order to identify its function, Ixonnexin (gi 67083505) was initially expressed in E. coli. Given the very 
low yield, chemical synthesis was next attempted. The peptide was synthesized using native chemical ligation 
methodology with yield of approximately 32%, as described in the Material and Methods Section. After refolding, 
Ixonnexin was purified by reverse-phase chromatography, and one single peak was detected (Fig. 1B) with yield of 
17%. Mass spectrometry analysis of Ixonnexin identified one single monomeric molecular mass of 11857.451 Da, 
which is in reasonable agreement with the theoretical mass of 11859.0 Da calculated for the correctly folded mol-
ecule with 3 oxidized disulphide bonds (Fig. 1C). SDS-PAGE shows that Ixonnexin migrates as a 20 kDa band, in 
denaturing and reducing conditions (Fig. 1C, inset). The molecular weight higher than expected is likely due to 
the basic pI 9.03 of the protein, which interferes with its migration. In order to verify whether Ixonnexin behaves 
as a monomer, or as higher-order oligomers, it was loaded onto a gel-filtration column previously calibrated with 
known molecular weight markers. The retention volume for Ixonnexin (11.91 ml) corresponds to a protein of 
23.3 kDa which is consistent with a non-covalent dimer.
We tested Ixonnexin in screening assays in order to identify its biological activity. Ixonexin at high molar 
excess did not promote small fluorogenic substrates hydrolysis nor inhibited the activity of 15 enzymes involved 
in coagulation or inflammation (Fig. 1D). However, it enhances amidolytic activity of FXa in 45% with IC50 of 
9.73 ± 2.5 nM (Fig. 1E) suggesting interaction with exosites33,34.
Because Ixonnexin contains several lysine residues in the C-terminal, and given the role of lysine in 
fibrin-mediated fibrinolysis6,35, it was hypothesized that Ixonnexin had a similar function, i.e., enhancing plasmin 
production by promoting the interaction of plasminogen with t-PA. Accordingly, Ixonnexin was immobilized in 
96-well microplates and incubated with plasminogen and t-PA; plasmin production was measured by the rate of 
S-2251 hydrolysis. Figure 1F shows that Ixonnexin promotes plasmin production in a dose-dependent manner, 
indicating that it positively modulates fibrinolysis in vitro. In contrast, Ixonnexin did not promote plasmin for-
mation when incubated with plasminogen and S-2251, in the absence of t-PA. These results imply that Ixonnexin 
is not a plasminogen activator. In order to verify if this effect was specific, several salivary proteins were immo-
bilized and tested for plasmin generation in the presence of plasminogen and t-PA. Figure 1F shows that only 
Ixonnexin among several other recombinant proteins is biologically active.
In order to identify Ixonnexin family members in tick saliva, 100 μl of saliva was fractionated by gel-filtration 
chromatography (Fig. 1G). Tandem MS/MS revealed that several peptides compatible with Ixonnexin are present 
between the retention times of 15 and 18 min. Quantitative proteomic analysis determined that Ixonnexin is 
among the most abundant salivary proteins (not shown). This result is congruent with I. scapularis transcriptome, 
which also estimates Ixonnexin among the most abundant transcripts28,29,36.
Ixonnexin is a potent modulator of fibrinolysis. We determined the kinetics of Ixonnexin-mediated 
plasmin generation. Ixonnexin dose-dependently enhances t-PA mediated fibrinolysis in the presence of 
Glu-plasminogen (Fig. 2A) or Lys-plasminogen (Fig. 2B) with maximum effect attained at 1 μg/well (highest 
tested concentration). Ixonnexin in solution also promotes fibrinolysis, although at a slightly slower rate than 
observed with immobilized protein (Fig. 2A,B, insets). In order to determine the Km of the reaction, Ixonnexin 
was incubated with increasing concentrations of plasminogen and reactions started with t-PA. Figure 2C,D, 
respectively shows the progress curves for plasmin generation as a function of time in the presence of Glu- 
or Lys-plasminogen, respectively. Figure 2E,F shows the transformation of the data as a function of the slope 
(A405 nm/min2) for Glu- and Lys-plasminogen, respectively. The calculated Km are 207.6 ± 40.03 nM and Vmax 
2.6 μM/min2 for Glu-plasminogen, and 72.83 ± 13.87 nM and Vmax of 3.1 μM/min2 for Lys-plasminogen, respec-
tively. This is 1000 lower than the Km calculated for t-PA induced plasminogen activation in the absence of fibrin, 
which is in the range of 19–65 μM4.
ε–Aminocaproic acid (ε-ACA) interferes with Ixonnexin activity. ε-ACA is a lysine analogue 
with antifibrinolytic properties that prevents the interaction of plasminogen Kringle domain with fibrin and 
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Figure 1. Synthesis and characterization of Ixonnexin, a novel modulator of fibrinolysis. (A) Clustal 
alignment of Ixonnexin (67083505; AAY66688.1) and other basic tail proteins from Ixodidae. (B) Ixonnexin 
was synthesized and the last purification step in RP-chromatography is shown. (C) Mass spectrometry of 
Ixonnexin. Inset, Purified Ixonnexin was loaded in a NuPAGE gel under reducing conditions. Gels were 
stained with Coomassie Blue. On the right, molecular mass markers are indicated. The arrow shows Ixonnexin. 
(D) Ixonnexin (250 nM) does not inhibit proteolytic activity of several enzymes involved in coagulation 
and inflammation65. (E) Ixonnexin increases catalytic activity of FXa (0.33 nM) measured with fluorogenic 
substrates. (F) Ixonnexin, but not other recombinant salivary proteins (1 μg/well), promotes plasmin generation. 
(G) Ixonnexin is expressed in tick saliva. The bar indicates the fraction where Ixonnexin were identified by 
proteomic analysis. A.u., arbitrary units. Representative experiments are shown.
www.nature.com/scientificreports/
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inhibits t-PA activity6,37. Figure 3A shows that ε-ACA increases Glu- plasminogen activation by t-PA in the 
presence of Ixonnexin at 3 and 10 mM, and an inhibitory effect is observed at 100 mM. This increase in activ-
ity has been explained by ε-ACA opening the conformation of Glu-plasminogen upon binding to LBS and 
Figure 2. Ixonnexin promotes plasmin generation initiated with t-PA. (A and B) Ixonnexin (0–1 μg/ml) was 
immobilized in 96-well plates and incubated with Glu- or Lys-plasminogen (0.5 μM), respectively. Reactions 
were initiated with t-PA (2.5 nM for Lys-plasminogen, or 10 nM for Glu-plasminogen), and plasmin formation 
was detected with chromogenic substrate S2251 (250 μM). The inset shows plasmin generation in solution. 
(C and D) Ixonexin (0.5 μg/ml) mediated plasmin generation in the presence of increasing concentrations of 
Glu- and Lys-plasminogen, respectively. (E and F) Show the transformation of the data in (C and D) as the slope 
A405 nm/min2 and Glu- and Lys-plasminogen concentration, respectively. Km of the reaction using Glu- or Lys-
plasminogen was calculated by non-linear regression, as indicated in Methods.
ka1 
(M−1s−1) kd1 (s−1) ka2 (s−1) kd2 (s−1) KD (nM) Rmax χ2
Glu-plasminogen 1.23 × 105 5.7 × 10−2 2.2 × 10−2 9.9 × 10–4 19.52 61.8 3.5
Lys-plasminogen 3.39 × 105 2.3 × 10–1 2.4 × 10−2 5.1 × 10−4 14.45 248.0 15.1
Single-chain t-PA 4.13 × 105 3.1 × 10−2 9.7 × 10−3 1.5 × 10−3 4.67 36.8 1.3
Two-chain t-PA 1.20 × 106 4.3 × 10−1 1.1 × 10−2 1.8 × 10−3 10.26 31.4 0.7
Plasmin 1.48 × 106 2.9 × 10−1 — — 197.40 305.8 27.7
Table 1. Kinetics of Ixonnexin interaction with components of the fibrinolytic system.
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enhancing activation by plasminogen activators such as urokinase6,37 and staphylokinase38. In contrast, when 
Lys-plasminogen is added as substrate, ε-ACA completely blocks plasmin generation at 3 mM (Fig. 3B). These 
results suggest that LBS plays a role in the interaction of Ixonnexin with components of the fibrinolytic system.
Figure 3. Effects of ε-aminocaproic acid on Ixonnexin-mediated plasmin formation. Immobilized Ixonnexin 
(0.5 μg/ml) was incubated with (A) Glu- or (B) Lys-plasminogen in the presence of ε-ACA. Reactions were 
initiated with t-PA (2.5 nM for Lys-plasminogen, or 10 nM for Glu-plasminogen), and plasmin formation was 
detected with chromogenic substrate S2251 (250 μM). Experiment was done in triplicate and SE bar is invisible.
Figure 4. Ixonnexin binds to plasminogen and t-PA. Ixonnexin was immobilized in a sensor chip and the 
following analytes were tested: (A) Glu-plasminogen (15–250 nM); (B) Lys-plasminogen (31–500 nM); (C) 
Single chain t-PA (7.8–125 nM); (D) Double chain t-PA (7.8–250 nM). Dissociation of the complexes was 
monitored for 600 seconds, and a two-state reaction binding model was used to calculate kinetic parameters. 
Representative sensograms are shown in black, and fitting of the data points is depicted in red. Representative 
experiments are shown.
www.nature.com/scientificreports/
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Ixonnexin displays high-affinity binding to plasminogen and t-PA. Kinetics of Ixonnexin inter-
action with plasminogen and t-PA were studied by SPR. Ixonnexin was immobilized in a carboxymethylated 
dextran sensor chip, and components of the fibrinolytic system used as analytes. Typical sensograms are shown 
in Fig. 4A–D. Best global fit was attained using 2-state model (conformational change) for plasminogen and t-PA 
with KD in the low nanomolar range. Although the fitting of the SPR experiments indicated a single binding site 
between ixonnexin and t-PA, we cannot exclude a second binding site with a lower affinity, suggested by the curve 
fitting at the highest plasminogen concentrations (Fig. 4). Nonetheless, the experiment indicates a high affinity 
interaction between Ixonnexin and t-PA. In addition, other models (e.g. 1:1 interaction, solution heterogeneity, 
surface heterogeneity, bivalent analyte) did not yield better fitting or lower χ2. Table 1 summarizes the kinetic 
values, Rmax and χ2 calculated for each interaction.
Ixonnexin does not bind urokinase. Urokinase has one single Kringle domain, and differs from plas-
minogen and t-PA, which have 5 and 2 Kringle domains, respectively. Urokinase also poorly interacts with fibrin, 
and does not rely on a colocalization mechanism like t-PA and fibrin6,35. Figure 5A shows that urokinase gen-
erates plasmin in the presence Lys-plasminogen, comparable to t-PA initiated reactions. However, immobilized 
Ixonnexin did not accelerate fibrinolysis, in contrast to reactions started with t-PA. Corroborating with these 
findings, immobilized Ixonnexin does not bind urokinase (Fig. 5B). Figure 5C also shows that Ixonnexin did not 
display high affinity binding to plasmin (Table 1), the product of the reaction.
Ixonnexin exhibits antithrombotic activity. To test whether Ixonnexin displays antithrombotic activity, 
we employed a mouse model of thrombosis in which FeCl3 induces carotid artery injury. Thrombus formation 
was estimated using a Doppler flow probe that allows monitoring of carotid blood flow for 60 minutes or until 
complete occlusion takes place. Figure 6 shows that the time to occlusion was not significantly different between 
control and mice treated with 100 µg/kg Ixonnexin; however, mice treated with 500 µg/kg were resistant to arterial 
occlusion. In these cases, occlusion did not take place before 60 minutes for most animals.
Figure 5. Ixonnexin does not bind to urokinase. (A) Ixonnexin was immobilized in 96-well plates as indicated 
and incubated with Lys-plasminogen. Reactions were initiated with urokinase (0.1 nM) or t-PA (2.5 nM), and 
plasmin formation was detected with chromogenic substrate S2251 (250 μM). SPR experiments: Ixonnexin 
was immobilized in a sensor chip and (B) urokinase (15–250 nM) or (C) plasmin (15–250 nM) were tested as 
analytes. Dissociation of the complexes was monitored for 600 seconds, and a two-state reaction binding model 
was employed for urokinase and Langmuir equation (1:1) for plasmin. Representative sensorgrams are shown in 
black, and fitting of the data points is depicted in red. Representative experiments are shown.
www.nature.com/scientificreports/
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Discussion
Ixonnexin, a member of the “Basic-tail” family of salivary proteins, is among the most abundant proteins in 
I. scapularis salivary glands. In this study, Ixonnexin was entirely obtained by chemical synthesis using native 
chemical ligation methodology followed by refolding and purification, resulting in a protein with a single molec-
ular mass. Ixonnexin is 83% identical to SALP14, a tick FXa anticoagulant expressed as a fusion protein with 
maltose-binding protein (MBP)31. In our experimental conditions, Ixonnexin, like MBP-SALP14, interacts with 
FXa. In contrast to MBP-SALP14, however, it augments the amidolytic activity of FXa, suggesting allosteric inter-
actions mediated by exosites33,34,39. These results provide additional evidence to conclude that Ixonnexin and 
SALP14 are anticoagulants. Notably, Ixonnexin was found to enhance fibrinolysis in vitro by a unique salivary 
mechanism. Accordingly, Ixonnexin supports the interaction of plasminogen and t-PA through formation of an 
enzymatically productive ternary complex. This assumption is based on (i) presence of several internal lysine 
residues in the C-terminus of Ixonnexin, (ii) high-affinity binding of Ixonnexin to plasminogen and t-PA, (iii) 
oligomerization as a non-covalent dimer, which may facilitate interaction with reactants, (iv) in vitro functional 
assays with purified proteins showing enhanced plasmin generation, (v) inhibition of this activity by ε-ACA, a 
lysine analogue, and (vi) Ixonnexin’s antithrombotic activity in vivo. Therefore, Ixonnexin is not a plasminogen 
activator, and differs from tick metalloproteases which promotes clot degradation by an enzymatic mechanism16, 
from “Tick Carboxypeptidase Inhibitor” (TCI) that targets TAFI through enzyme-inhibitor [EI] complex forma-
tion18, and from enolase which operates as a surface-bound plasminogen receptor19,40.
Despite obvious differences in the primary sequence, it is worth noting that Ixonnexin mimics polymerized 
fibrin in several respects. Accordingly, fibrin displays C-terminal lysine residues that function as a high-affinity 
binding site for the LBS in the Kringle domains of plasminogen and t-PA6,41. As a result, fibrin-mediated acti-
vation of fibrinolysis promotes a decrease in the Km from 19–65 μM to 0.14 μM for plasminogen4. Similarly, 
Ixonnexin decrease the Km of the reaction in ~1000 fold4. Moreover, ixonnexin, like fibrin6,41, does not enhance 
urokinase-mediated fibrinolysis. We propose that Ixonnexin operates as a “soluble fibrin” promoting assembly of 
fibrinolysis, as reported for annexin-2/S100 complex42,43 and Prion Protein44 among others proteins19,40.
Ixonnexin binds plasminogen which is present in plasma at high concentrations (1.5–2 μM) approximately 
100 times higher than the KD (~10 nM) of the interaction. This finding is relevant for Ixonnexin’s mecha-
nism of action suggesting that it remains bound to plasminogen, which has plasma half-life of 48 hours35. The 
zymogen-binding property of Ixonnexin resembles Ixolaris mechanism of action, which binds to FX exosite39 
and serves as a scaffold for inhibition of FVIIa/TF complex, with a long lasting antithrombotic effect of 24 hrs45,46. 
Ixonnexin therefore is another example of a protein with more than one target and distinct mechanisms of action. 
In fact, multifunctional proteins are increasingly recognized in salivary gland secretions47–51.
In vivo experiments show that Ixonnexin given intravenously to mice 15 minutes before carotid artery 
injury with FeCl3 prolongs time to occlusion. This indicates that Ixonnexin interferes with thrombus forma-
tion. Nevertheless, additional studies are required to understand the relative contribution of anticoagulant vs 
pro-fibrinolytic activity determined here in vitro, and the relevance of these findings for Ixonnexin’s antithrom-
botic activity in vivo and whether it is associated with bleeding.
Our results are pertinent in tick biology since a potent fibrinolytic enzyme is present in tick saliva16. Because 
a plasminogen activator has not been identified in the saliva incubated with plasminogen and chromogenic sub-
strate S-2251 (not shown), it is conceivable that host t-PA employs Ixonnexin, not fibrin, as a cofactor to initiate 
fibrinolysis. Also, Ixonnexin C-terminal residue is phenylalanine while TAFI, a carboxypeptidase, has specificity 
for lysine7,8,52. Additionally, Ixonnexin is abundantly expressed in Ixodes sp, according to transcriptome28–30,36, 
gene expression36,53 and proteome studies (Fig. 1G), suggesting that it may reach high concentrations necessary to 
inhibit coagulation and/or stimulate fibrinolysis in the feeding cavity. Of note, D-dimers are found in I. scapularis 
ticks feeding on the host, indicating that fibrinolysis mediated by plasmin does occur at sites of attachment54. 
Figure 6. Ixonnexin exhibits antithrombotic activity in vivo. (A) A paper filter imbibed with 7.5% FeCl3 was 
applied to carotid artery, and blood flow was monitored with a perivascular flow probe for 60 minutes or until 
stable occlusion took place. Fifteen minutes before injury, Ixonnexin was injected into the caudal vein of the 
mice. Each symbol represents 1 animal (n = 7). p < 0.001 (0.5 mg/Kg vs control).
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Moreover, silencing of SALP14 in the salivary gland, which presumably also has pro-fibrinolytic activity given 
its conserved “basic tail”, is accompanied by reduced ability of ticks to feed resulting in a decline in engorgement 
weights55. Finally, Ixonnexin family is expanded in Amblyomma sp56, Hyalomma sp57, Rhipicephalus sp58, Antricola 
sp59 and Ornithodorus sp ticks28. Altogether, these results highlight the importance of the “basic-tail” family of 
salivary proteins in tick biology. Furthermore, the fibrinolytic system is critical for Borrelia sp infection since 
mice lacking plasminogen have impaired dissemination27 raising the possibility that Ixonnexin contributes to 
parasite-vector-host interactions20–26. We speculate that mosquitoes, bugs and sandflies may rely in unknown 
function salivary proteins in order to promote fibrinolysis by a similar mechanism described here for Ixonnexin; 
this activity may contribute to parasite transmission to the host and/or the vector.
Ixonnexin adds to the repertoire of modulators of hemostasis present in I. scapularis saliva9–15. Identification 
of Ixonnexin as a novel fibrinolysis modulator is relevant to study the participation of plasmin in ischemic events, 
tumor growth, metastasis5,60,61 and Borrelia sp. transmission22–26. Ixonnexin may be useful as a prototype for the 
development of novel drugs with therapeutic potential.
Material and Methods
Ethical Statement. All animal care and experimental protocols were conducted following the NIH 
Guide for the Care and Use of Laboratory Animals (ISBN 0-309-05377-3) guidelines and the Committee for 
Evaluation of Animal Use for Research from the Federal University of Rio de Janeiro, CAUAP-UFRJ under reg-
istry #IBQM/081-05/16. Technicians dedicated to the animal facility carried out all aspects related to mouse 
husbandry under strict guidelines for careful and consistent care and handling of the animals.
Reagents. Glu- and Lys-plasminogen, plasmin, low molecular weight urokinase and single or double chain 
t-PA were from Enzyme Research Laboratories (South Bend, IN) or Innovative Research (Novi, MI). Activated 
partial thromboplastin time (aPTT; STA-PTT Automate) and prothrombin time (PT; Neoplastine CI Plus) 
reagents were from Diagnostica Stago (Asnières, France). S-2251 (H-D-Valyl-L-leucyl-L-lysinep-Nitroaniline 
dihydrochloride) was obtained from Diapharma (West Chester, OH). ε-Aminocaproic acid (ε-ACA), 
4-mercaptophenylacetic acid, trifluoroacetic acid (TFA), triisopropylsilane (TIS), diisopropylcarbod-
iimide (DIC), 3,6-Dioxa-1,8-octane-dithiol (DODT), 4-methylpiperidine, methyl t-butyl ether (MTBE) 
and tris(2-carboxyethyl)phosphine hydrochloride (TCEP) were from Sigma (Saint Louis, MO). HBTU, 
N,N-diisopropylethylamine (DIPEA) and 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) were from Chem-Impex 
International (Wood Dale, IL). Fmoc-amino acid for peptide synthesis were from Midwest Biotech Inc (Fishers, 
IN). Dimethylformamide (DMF) and N-methylpyrrolidone (NMP) were from AGTC Bioproducts (Framingham, 
MA).
Tick saliva and Mass spectrometry. I. scapularis ticks were reared at the University of Rhode Island and 
were fed on rabbits. Saliva collection and salivary gland homogenates were obtained as reported62. Proteomic 
analysis of saliva was performed as described63.
Synthesis of Ixonnexin. Full length Ixonnexin (gi 67083505) has 21 residues in the signal peptide with 
cleavage site between positions Ala21 and His22: AAA-HN (Signal P 4.1 server). Mature Ixonnexin (104 resi-
dues) was synthesized by ligation of separately synthesized fragment (51–104) with the C-terminal thioester of 
fragment (1–50), utilizing Native Chemical Ligation (NCL)64 methodology followed by folding of the ligation 
product.
Ixonnexin fragment (51–104). It was synthesized using an automated peptide synthesizer, model 433 A 
(Applied Biosystems, Fullerton, CA, USA) with Fmoc strategy and HBTU/DIPEA as the coupling reagent. 
Novabiochem Fmoc-Phe-Wang-LL resin (0.20 mmol) (EMD Millipore, division of Merck KGaA, Darmstadt, 
Germany) was used as the solid phase. The side-chain protecting groups used in synthesis were Trt for Asn, 
Cys, Gln, and His; OtBu for Glu and Asp; Pbf for Arg; and tBu for Ser, Thr, and Tyr. The coupling reaction 
time was 1 h, and 4-methylpiperidine (20%)/N-methylpyrrolidone was used to remove the Fmoc group at every 
step. Peptide resin was washed with N-methylpyrrolidone and dichloromethane and dried in vacuo to yield the 
protected peptide-resin. The peptide resin was treated with a cleavage mixture of trifluoroacetic acid/water/
Triisopropylsilane/3,6-Dioxa-1,8-octane-dithiol (92.5∶2.5∶2.5∶2.5, v/v/v/v; 40 ml) for 2.5 h to remove protecting 
groups and peptide from the resin. After filtration of the exhausted resin, the solvent was concentrated in vacuo 
and the residue was triturated with methyl t-butyl ether. The solid peptide was filtered off, washed with methyl 
t-butyl ether, and vacuum dried. The crude peptide was purified by preparative reversed-phase high-performance 
liquid chromatography (HPLC), and purity grade was checked by analytical HPLC analyses and mass spectrome-
try using a matrix-assisted laser desorption ionization time-of-flight mass spectrometer Axima CFR + (Shimadzu 
Scientific Instruments. Columbia, MD, USA). Pure fractions were combined, frozen, and lyophilized to afford 
Ixonnexin (51–104) peptide. Peptide was 95% pure (MALDI-TOF MS: m/z calculated 6035.9, found 6037.1 
[M + H+]).
Ixonnexin fragment (1–50) thioester. It was synthesized using an automated peptide synthesizer, model 
433 A (Applied Biosystems, Fullerton, CA, USA) with Fmoc strategy and HBTU/DIPEA as the coupling reagent. 
Novabiochem Fmoc-Thr(tBu)-2-ClTrt resin (0.30 mmol) (EMD Millipore, division of Merck KGaA, Darmstadt, 
Germany) was used as the solid phase. The side-chain protecting groups used in synthesis were Trt for Asn, Cys, 
and His; OtBu for Glu and Asp; Pbf for Arg; and tBu for Ser, Thr, and Tyr. The coupling reaction time was 1 h, and 
4-methylpiperidine (20%)/N-methylpyrrolidone was used to remove the Fmoc group at every step. Following 
the final Fmoc deprotection, the N-terminal amino group was protected with Boc group by reacting the peptide 
resin with di-t-butyl dicarbonate and DIPEA in dimethylformamide (DMF). After washing with DMF and t-butyl 
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methyl ether and drying in vacuum, the fully protected peptide resin was treated with the HFIP/dichlorometh-
ane (1:3, v/v, 3 × 15 min) mixture, collecting all filtrates. The combined filtrates were concentrated in vacuum 
and the residue was triturated with methyl t-butyl ether (30 mL) to yield a white precipitate. Filtration, washing 
with methyl t-butyl ether and drying afforded a fully protected peptide fragment with a free C-terminal carboxy 
function. This solid peptide was treated with ethyl ß-mercaptoacetate (TCI America, Portland, OR), diisopro-
pylcarbodiimide (DIC), and DIPEA (5 equiv.each) in DMF for 18 hrs followed by removal of the solvent in high 
vacuum and trituration of the oily residue with methyl t-butyl ether and separation of the precipitate by filtration. 
After drying in vacuum, the crude thioester was treated with a cleavage mixture of trifluoroacetic acid(TFA)/
water/triisopropylsilane/3,6-Dioxa-1,8-octane-dithiol (DOTH) (92.5∶2.5∶2.5∶2.5, v/v/v/v; 30 ml) for 2.0 h to 
remove protecting groups. After concentration and trituration with the cold ethyl ether, the crude solid peptide 
thioester was filtered off, washed with ethyl ether and dried. The pure thioester of Ixonnexin (1–50) fragment was 
isolated by preparative reverse-phase HPLC and its purity checked by HPLC analyses and mass spectrometry 
using a matrix-assisted laser desorption ionization time-of-flight mass spectrometer Axima CFR + (Shimadzu 
Scientific Instruments). Pure fractions were combined, frozen, and lyophilized to afford pure C-terminal thioester 
(MALDI-TOF MS: m/z calculated 5965.4, found 5966.8 [M + H+]).
Ligation of Ixonnexin fragment (1–50) thioester and Ixonnexin fragment (51–104). Purified 
Ixonnexin (1–50) thioester 2.0 µM and Ixonnexin (51–104) 2.3 µM were dissolved in 1.9 mL of 6 M guanidine 
hydrochloride/200 mM PBS buffer containing 4-mercaptophenylacetic acid (Sigma-Aldrich, St.Louis, 68 mg) and 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Sigma-Aldrich, St.Louis, 68 mg). The pH of the mixture was 
adjusted to 7.1 with 6 M sodium hydroxide and the resultant solution was kept at room temperature, monitoring 
ligation progress by analytical HPLC using a gradient of acetonitrile/water with UV monitoring at 215 nm. After 
24 hrs the reaction mixture was acidified with diluted (~2%) TFA and the product was isolated by preparative 
reverse-phase HPLC and its purity checked by HPLC analyses and MALDI-TOF mass spectrometry. Pure frac-
tions were combined, frozen, and lyophilized to afford pure unfolded Ixonnexin 1–104 with 32% theoretical yield 
(MALDI-TOF MS: m/z calculated 11867.1, found 11868.0 [M + H+]).
Folding of Ixonnexin. Linear, purified peptide Ixonnexin (1–104, mature protein) was dissolved in 6 M gua-
nidin•HCl/200 mM PBS at a concentration of 2 mmol, and the solution was introduced by a Harvard Apparatus 
“Elite 11” through a syringe, to a 30 times larger volume of the stirred solution of degassed, 50 mM Tris/1 mM 
EDTA, pH∼8, containing reduced glutathione and oxidized glutathione at concentrations of 1.6 mM and 0.2 mM, 
respectively. The progress of folding was monitored by HPLC using a gradient of acetonitrile/water with UV 
monitoring at 215 nm. After 3 h, the reaction mixture was acidified with 2% trifluoroacetic acid to pH 5. The 
folded peptide was isolated by preparative reverse-phase HPLC and its purity checked by HPLC analyses and 
mass spectrometry using a matrix-assisted laser desorption ionization time-of-flight mass spectrometer Axima 
CFR + (Shimadzu Scientific Instruments). Pure fractions were combined, frozen, and lyophilized to afford pure, 
folded peptide with 17% theoretical yield. Extinction coefficient of Ixonnexin at 280 nm is 15845 (all disulfide 
bonds); A280 nm/cm (1 mg/mL), 1.33. (MALDI-TOF MS: m/z calculated 11861.0, found 11863.0 [M + H+]).
Gel-filtration chromatography. Ixonnexin was loaded onto a Superdex 75 10/300 (GE Healthcare) col-
umn equilibrated in 20 mM Tris-HCl, NaCL 0.15 M, pH 8 with a flow of 0.5 mL/min and connected to AKTA 
purifier system (Amersham Biosciences, Uppsala, Sweden) Pharmacia HPLC system. Protein was detected by 
peak absorbance at 280 and 220 nm. Column was calibrated with the following recombinant salivary proteins 
with respective mol wt and retention volumes: D7 (26.7 kDa, 11.64 ml), 9G11 (14.4 kDa, 12.90 ml), FS50 (8.1 kDa, 
13.49 ml). The log of mol wt markers was plotted vs the retention volumes resulting in a straight line where reten-
tion volumes are interpolated.
PAGE. The samples were treated with 4 × NuPAGE lithium dodecyl sulfate sample buffer and analyzed in 
NuPAGE 4% to 12% gels with 2-(N-morpholino)ethanesulfonic acid running buffer.
Plasminogen activation assays. Ixonnexin, or other recombinant salivary proteins (in 100 μl PBS, 0–1 μg/
well) were immobilized overnight in 96-well plates (Costar). Wells were washed 3 times in TBS containing 0.03% 
BSA and 5 mM CaCl2 (TBS-BSA buffer). Glu- or Lys-plasminogen (0.5 μM) and S2251 (250 μM) was added to 
the wells and incubated for 30 min at room temperature. Then, single chain t-PA (10 nM for Glu-plasminogen, or 
2.5 nM for Lys-plasminogen) or urokinase (0.1 nM for Lys-plasminogen) were added to start reactions, in a final 
volume of 100 μl. Plasmin generation was detected at A405 nm at 37 °C, using ELISA reader as described65. Initial 
rates of plasmin generation were calculated using linear regression analysis of plots of absorbance (A405 nm) vs 
time (min)2, as described66–68 using GraphPad Prism (La Jolla, CA). A standard curve for substrate hydrolysis was 
performed with p-nitroanilide (Sigma). In some experiments, ε-ACA was incubated with the reactants.
Surface Plasmon Resonance. All surface plasmon resonance (SPR) experiments were carried out in a 
T100 instrument (Biacore Inc, Uppsala, Sweden) following the manufacturer’s instructions. For immobilization 
using an amine coupling kit (Biacore), carboxymethylated dextran chips were activated with 1-ethyl-3-(dimeth-
ylaminopropyl) carbodiimide, and N-hydroxysuccinimide before injection of Ixonnexin (10 µg/mL) in acetate 
buffer, pH 5.5. Remaining activated groups were blocked with 1 mol/L ethanolamine, pH 8.5, resulting in a final 
immobilization of 726.2 RU. Kinetic experiments were carried out by injecting plasminongen, urokinase or t-PA 
for a contact time of 120 seconds at a flow rate of 30 µL/minute at 25 °C as described65. After subtraction of the 
contribution of the bulk refractive index and non-specific interactions with the CM5 chip surface, the individual 
association (ka) and dissociation(kd) rate constants were obtained by global fitting of the data using the two-state 
reaction (conformational change) interaction model in BIAevaluation software (Biacore Inc.). In this model, the 
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analyte (A) binds to the ligand (B) to form an initial complex (AB) and then undergoes subsequent binding or 
conformational change to form a more stable complex (AB*). Model parameters are: ka1, association rate con-
stant for analyte binding; kd1, dissociation rate constant for analyte from the complex; ka2, forward rate constant 
for the conformational change; kd2, reverse rate constant for the conformational change. These values were then 
used to calculate the dissociation constant (KD). The values of mean squared residual obtained were not signif-
icantly improved by fitting data to models that assumed other interactions. Conditions were chosen so that the 
contribution of mass transport to the observed values of KD was negligible. In addition, the models in the T100 
evaluation software fit for mass transfer coefficient to mathematically extrapolate the true ka and kd.
FeCl3-Induced Artery Thrombosis. Thrombus formation was induced by applying a piece of filter paper 
(1 × 2 mm) saturated with 7.5% FeCl3 solution on the adventitial surface of the artery for 3 minutes. After expo-
sure, the filter paper was removed, and the vessel was washed with sterile normal saline. Carotid blood flow was 
continuously monitored for 60 minutes or until complete occlusion (0 flow for at least 10 seconds) occurred as 
reported69.
Protease Inhibition Assays. This was performed essentially as described65,70.
Statistical analysis. Results are expressed as means ± SE. Statistical differences among the groups were ana-
lyzed by t test. Significance was set at P ≤ 0.05 (Graph-Pad Prisma software, La Jolla, CA).
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